Cantel Medical Corp. (CMD) Receives Consensus Recommendation of “Buy” from Analysts
Cantel Medical Corp. (NYSE:CMD) has received a consensus broker rating score of 2.00 (Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a hold recommendation and two have assigned a strong buy recommendation to the company. Cantel Medical Corp.’s rating score has improved by 14.2% in the last three months as a result of various analysts’ upgrades and downgrades.
Analysts have set a 1-year consensus price target of $100.00 for the company and are expecting that the company will post $0.52 EPS for the current quarter, according to Zacks. Zacks has also given Cantel Medical Corp. an industry rank of 97 out of 265 based on the ratings given to related companies.
CMD has been the subject of a number of research analyst reports. Sidoti raised Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 target price for the company in a research report on Wednesday, August 2nd. Zacks Investment Research raised Cantel Medical Corp. from a “hold” rating to a “buy” rating and set a $83.00 target price for the company in a research report on Tuesday, August 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Cantel Medical Corp. in a research report on Thursday, June 8th. Finally, Benchmark Co. lowered Cantel Medical Corp. from a “buy” rating to a “hold” rating in a research report on Friday, June 9th.
Cantel Medical Corp. (NYSE CMD) traded up 1.51% during trading on Friday, reaching $85.17. The company’s stock had a trading volume of 454,855 shares. The company has a market capitalization of $3.54 billion, a P/E ratio of 50.40 and a beta of 1.23. Cantel Medical Corp. has a 12-month low of $68.19 and a 12-month high of $88.81. The firm’s 50-day moving average price is $77.92 and its 200 day moving average price is $76.68.
In related news, Chairman Charles M. Diker sold 35,000 shares of the company’s stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $75.52, for a total transaction of $2,643,200.00. Following the transaction, the chairman now directly owns 3,114,520 shares of the company’s stock, valued at approximately $235,208,550.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 14.90% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Principal Financial Group Inc. acquired a new position in Cantel Medical Corp. during the 2nd quarter valued at about $21,919,000. Rhumbline Advisers acquired a new position in Cantel Medical Corp. during the 2nd quarter valued at about $5,892,000. Connable Office Inc. acquired a new position in Cantel Medical Corp. during the 2nd quarter valued at about $256,000. Pennsylvania Trust Co acquired a new position in Cantel Medical Corp. during the 2nd quarter valued at about $6,590,000. Finally, Virginia Retirement Systems ET AL acquired a new position in Cantel Medical Corp. during the 2nd quarter valued at about $2,672,000. 84.28% of the stock is currently owned by institutional investors.
About Cantel Medical Corp.
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.